Johnson & Johnson reported strong Q2 results, with Spravato sales up 41.1% YoY to $584 million. The company also raised its 2026 adjusted diluted EPS guidance to $11.60–$11.75 from $11.45–$11.65, indicating improved earnings momentum into 2026.
Johnson & Johnson reported strong Q2 results, with Spravato sales up 41.1% YoY to $584 million. The company also raised its 2026 adjusted diluted EPS guidance to $11.60–$11.75 from $11.45–$11.65, indicating improved earnings momentum into 2026.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
